Concepedia

Author

David D’Cruz

St Thomas' HospitalORCID

Also Known As

D D'Cruz, D D'cruz, D D’Cruz, D P D'CRUZ, D P D'Cruz, D P D’Cruz, D'Cruz, D, D'Cruz, D.P., D'Cruz, DP, D'Cruz, David

496

Publications

18.1K

Citations

64

H-Index

148

Concepts

All Affiliations

St Thomas' HospitalGuy's and St Thomas' NHS Foundation TrustKing's College LondonUniversity of BirminghamUniversity College London
DD

About

David D’Cruz is an author at St Thomas' Hospital specializing in medicine, autoimmune disease, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

44

2.4K

2

Public Health

4

4

102

3

Health Sciences

2

2

61

4

Nursing

1

1

40

5

Social Sciences

1

1

12

David D’Cruz

×

136

Publications

12.3K

Citations

55

H-Index

YearCitations

Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors

Jérôme Cros, Nicolas Cagnard, Kevin Woollard,

Immunity

2010

1.2K

Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide

Frédéric Houssiau, Carlos Vasconcelos, David D’Cruz,

Arthritis & Rheumatism

2002

1.1K

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

David Isenberg, Anisur Rahman, Elizabeth Allen,

Lara D. Veeken

2005

616

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

Frédéric Houssiau, David D’Cruz, Shirish Sangle,

Annals of the Rheumatic Diseases

2010

489

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Susan Manzi, Jorge Sánchez‐Guerrero, Joan T. Merrill,

Annals of the Rheumatic Diseases

2012

396

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long‐term followup of patients in the Euro‐Lupus Nephritis Trial

Frédéric Houssiau, Carlos Vasconcelos, David D’Cruz,

Arthritis & Rheumatism

2004

382

The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial

Joan T. Merrill, Rubén Burgos‐Vargas, René Westhovens,

Arthritis & Rheumatism

2010

371

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis

Chloe Lapraik, Richard A. Watts, Paul Bacon,

Lara D. Veeken

2007

369

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed,

Lara D. Veeken

2017

339

Autoantibodies to extracellular matrix protein 1 in lichen sclerosus

Noritaka Oyama, Ien Chan, S. M. Neill,

The Lancet

2003

311

Page 1